NASDAQ:ICLR Stock Quote
Icon Plc is a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries
The company specializes in offering a comprehensive range of services that encompass a wide array of phases in the drug development process, from early-stage research and clinical trials to regulatory submissions and post-market support. With a focus on advancing healthcare innovations, Icon collaborates closely with its clients to optimize their product development strategies, improve operational efficiency, and accelerate the path to market for new therapeutic products. Their expertise encompasses various therapeutic areas, providing tailored solutions that address the specific needs of each client.
Frequently Asked Questions
How does ICON plc contribute to innovation in clinical trials?
ICON plc contributes to innovation in clinical trials through the incorporation of advanced technologies such as artificial intelligence, big data analytics, and real-world evidence. By leveraging these tools, ICON aims to optimize clinical trial design, improve patient recruitment, and enhance data collection, ultimately leading to faster and more efficient drug development.
How does ICON plc ensure quality in its services?
ICON plc prioritizes quality assurance throughout its operations by implementing rigorous standard operating procedures and compliance protocols. The company employs a dedicated quality assurance team responsible for conducting audits, monitoring performance, and ensuring adherence to industry standards and regulatory requirements in all of its projects.
How does ICON plc maintain client relationships?
ICON plc maintains strong client relationships by prioritizing communication, collaboration, and personalized service. By working closely with clients to understand their unique needs and challenges, ICON fosters long-term partnerships that drive success in clinical development and commercialization efforts.
How has ICON plc adapted to the COVID-19 pandemic?
ICON plc has adapted to the COVID-19 pandemic by implementing remote working practices, utilizing digital tools for data management, and modifying clinical trial methodologies to account for safety and compliance challenges. The company has focused on maintaining trial continuity and supporting clients in navigating the complexities introduced by the pandemic.
Is ICON plc publicly traded?
Yes, ICON plc is publicly traded on the NASDAQ stock exchange under the ticker symbol ICLR. The company went public in 2000, and its shares are accessible to investors seeking exposure to the clinical research and development sector.
What are ICON plc’s corporate social responsibility initiatives?
ICON plc is committed to corporate social responsibility through various initiatives that focus on sustainability, community engagement, and ethical practices. The company strives to minimize its environmental impact, support local communities, and uphold strong ethical standards in its operations, contributing positively to society at large.
What does ICON plc do?
ICON plc is a global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The company plays a crucial role in supporting clients throughout the drug and device development life cycle, offering services ranging from clinical trial management and laboratory services to regulatory consulting and post-market commercialization.
What industries does ICON plc serve?
ICON plc primarily serves the pharmaceutical, biotechnology, and medical device industries. By offering tailored solutions across these sectors, the company aims to support its clients in the development of new therapies and medical technologies while ensuring compliance with regulatory standards.
What initiatives does ICON plc have for diversity and inclusion?
ICON plc is committed to promoting diversity and inclusion within its workforce and organizational culture. The company actively seeks to recruit individuals from diverse backgrounds, implements initiatives to support underrepresented groups, and fosters an inclusive work environment that values different perspectives and experiences.
What is ICON plc's market position?
ICON plc is one of the leading global players in the clinical research industry. The company is recognized for its innovative solutions and commitment to quality, placing it in a strong competitive position relative to other contract research organizations. ICON's extensive experience and established reputation have helped it to maintain a significant market share.
What is ICON plc’s approach to employee development?
ICON plc values employee development and invests in ongoing training, education, and professional growth opportunities for its workforce. The company encourages a culture of continuous learning, ensuring that employees are equipped with the latest skills and knowledge to excel in the fast-evolving clinical research landscape.
What is ICON plc’s fiscal performance like?
ICON plc has demonstrated strong fiscal performance in recent years, showcasing consistent revenue growth and profitability. The company has successfully navigated market challenges and capitalized on opportunities, reflecting its robust business model and strategic vision in the clinical research industry.
What is ICON plc’s strategy for future growth?
ICON plc’s strategy for future growth includes expanding its service offerings, enhancing technology capabilities, and pursuing acquisitions that align with its business goals. The company aims to strengthen its global footprint, reach new markets, and continue delivering innovative solutions that meet the evolving needs of its clients.
What is the significance of ICON plc's global presence?
ICON plc's global presence is significant because it allows the company to conduct clinical trials across diverse populations and regulatory environments. This capability enables ICON to meet clients' needs effectively, facilitate faster recruitment of participants, and provide comprehensive insights that can lead to successful drug approvals and market entry.
What recent acquisitions has ICON plc made?
ICON plc has made several strategic acquisitions in recent years to expand its capabilities and market reach. Notable acquisitions include companies that enhance ICON's expertise in specific therapeutic areas, technology platforms, and services that complement its existing offerings, thereby improving its overall service delivery.
What types of services does ICON plc offer?
ICON plc offers a wide range of services that include clinical trial management, biostatistics, data management, regulatory affairs consulting, pharmacovigilance, and post-market support. Their comprehensive offerings are designed to streamline the development process for drugs and devices, making it easier for clients to bring their innovations to market.
When was ICON plc founded?
ICON plc was founded in 1990. Since its establishment, the company has rapidly grown both organically and through strategic acquisitions, expanding its range of services and global footprint in the clinical research space.
Where is ICON plc headquartered?
ICON plc is headquartered in Dublin, Ireland. The company has a comprehensive international presence, with offices and operations across North America, Europe, Asia, Latin America, and Africa, enabling it to effectively serve clients and facilitate clinical trials around the world.
Who are ICON plc's main clients?
ICON plc's primary clients include pharmaceutical companies, biotechnology firms, medical device manufacturers, and contract research organizations. The company works with a diverse array of clients, ranging from large multinational corporations to smaller start-ups, to support the clinical development of life-saving drugs and technologies.
What is the current price of ICON plc - Ordinary Shares?
The current price of ICON plc - Ordinary Shares is 169.18
When was ICON plc - Ordinary Shares last traded?
The last trade of ICON plc - Ordinary Shares was at 3:51 pm EDT on April 2nd, 2025
What is the market capitalization of ICON plc - Ordinary Shares?
The market capitalization of ICON plc - Ordinary Shares is 8.96B
How many shares of ICON plc - Ordinary Shares are outstanding?
ICON plc - Ordinary Shares has 52.96M shares outstanding.